The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.64
Bid: 3.64
Ask: 3.28
Change: 0.17 (4.90%)
Spread: -0.36 (-9.89%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.47
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wilbur Ellis Agreement

14 Jun 2023 07:00

RNS Number : 6732C
Plant Health Care PLC
14 June 2023
 

14 June 2023

 

Plant Health Care plc

 ("Plant Health Care" or the "Company")

 

Plant Health Care® ("PHC") and Wilbur-Ellis® Agribusiness Announce Distribution Agreement to Support First OBRONATM Commercial Sales in the U.S.

 

Plant Health Care® (AIM.PHC.L), a leading provider of peptides for plant protection to global agriculture markets, is pleased to announce it has concluded a distribution agreement ("The Agreement") with Wilbur-Ellis® Agribusiness, one of the largest U.S. retailers of agricultural products. The Agreement will support commercial sales of OBRONATM, a foliar fungicide recently approved by US EPA which is expected to be available within key US markets during the summer of 2023. Obrona is a unique product developed to help growers control a wide range of fungal and bacterial plant pathogens within fruits, nuts, vegetables, and row crops.

 

Plant Health Care and Wilbur-Ellis have been working together in an exclusive partnership since 2020 to evaluate and develop PHC279, the active ingredient in OBRONA, for high value specialty and row crop markets. Multiple years of field trials have validated product efficacy to support initial launch focused on corn diseases, such as tar spot (Phyllachora maydis), Gray leaf spot (Cercospora zeae-maydis), and common rust (Puccinia sorghi), as well as powdery and downy mildew and various other diseases in grapes, as well as white mold (Sclerotinia sclerotiorum) and other diseases affecting leafy vegetables within key Western US states.

 

Derived from naturally occurring proteins, PHC279 is the first product from the Company's PREtec technology platform (Vaccines for Plants™) that will be available to US farmers. PREtec stimulates crop growth and enhances crop resistance to fungal and bacterial diseases and improves crop quality and yield. The Company's initial PREtec product, Saori® is successfully being used in Brazil as a seed treatment to control an array of soybean diseases including Asian Soybean Rust (Phakopsora spp.).

 

PREtec provides growers with a novel and environmentally friendly approach to growing crops and is compatible with mainstream agricultural practices. As part of an integrated pest management program, OBRONA will reduce reliance on older synthetic pesticides and will provide growers with a valuable tool to proactively manage disease resistance. The availability of OBRONA will support farmers seeking to use more sustainable and environmentally friendly practices while continuing to provide safe, abundant, and high-quality food.

 

Plant Health Care continues to expand into new markets around the world through strategic partnerships with major global distribution partners. The Company is on track to achieve revenue of $30 million by 2025, through the launch of new products and continued growth through current and future distributor relationships, and to achieve cash breakeven and profit along that track.

 

Jeff Tweedy, CEO of Plant Health Care, said: ‟Having worked with Wilbur-Ellis on the development of OBRONA for more than three years, I am gratified that this new agreement will bring OBRONA to the market to enable control of many of the most recalcitrant fungal and bacterial pathogens challenging growers today. OBRONA will support sustainable agriculture with better crops delivering higher yield for thousands of U.S. farmers."

 

 

Scott Addy, Wilbur-Ellis Agribusiness VP Branded Technologies and Biological Solutions, said: "We are pleased that our partnership with Plant Health Care has resulted in the approval of OBRONA and are looking forward to launching the product this summer to deliver value to the grower in a sustainable way. We expect that there will be many other products that follow, and we will continue to offer our growers biological options to solve their pest issues."

 

 

# # #

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes, and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

About the Wilbur-Ellis Companies 

 

Founded in 1921, the Wilbur-Ellis companies are leading marketers, distributors and manufacturers of agricultural products and animal nutrients. By developing strong relationships, making strategic market investments, and capitalizing on new opportunities, the Wilbur-Ellis companies have continued to grow the business with sales of over $3.5 billion. For more information, please visit www.wilburellis.com

 

For further information, please contact: 

Plant Health Care plc Jeff Tweedy, CEO

Tel: +1 919 926 1600

Cenkos Securities plc - Nomad & Broker Neil McDonald / Pete Lynch

Tel: +44 (0) 131 220 9771

SEC Newgate (Financial Communications) Robin Tozer / George Esmond / Harry Handyside

Tel: +44 (0)7540 106 366 Email: phc@secnewgate.co.uk

For further information about Wilbur-Ellis, please contact:

Jeanne Forbis, email:jforbis@wilburellis.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEASKLFDLDEEA
Date   Source Headline
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding
20th Apr 20227:00 amRNSHolding(s) in Company
19th Apr 20221:46 pmRNSNotice of results and investor presentation
11th Apr 202212:52 pmRNSHolding(s) in Company
1st Apr 20227:00 amRNSNew Distribution agreement with Ager Agro
14th Mar 202212:49 pmRNSHolding(s) in Company
11th Mar 202212:19 pmRNSHolding(s) in Company
3rd Feb 202212:56 pmRNSHolding(s) in Company
1st Feb 20221:16 pmEQSPlant Health Care, plc
1st Feb 20227:00 amRNS2021 Trading Statement
31st Jan 20227:00 amRNSPHC949 product registration submitted to the EPA
17th Jan 20227:00 amRNSInvestor Presentation
15th Dec 20217:00 amRNSWilbur Ellis and Plant Health Care discussion
13th Dec 20217:00 amRNSCommercial scale manufacturer for Saori
30th Nov 20214:36 pmRNSPrice Monitoring Extension
20th Oct 20216:03 pmRNSExercise of Options
22nd Sep 20217:00 amRNSNew agreement with Nutrien for Saori launch
22nd Sep 20217:00 amRNSInterim Report 30 June 2021
21st Sep 20214:41 pmRNSSecond Price Monitoring Extn
21st Sep 20214:35 pmRNSPrice Monitoring Extension
1st Sep 20217:00 amRNSArgentina approves Harpin as a seed treatment
24th Aug 20217:00 amRNSInvestor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.